digifab.co.uk Report : Visit Site

Technical data of the digifab.co.uk

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host digifab.co.uk. Currently, hosted in United States and its service provider is Prolexic Technologies Inc. .

the related websites

mhra.gov.uk bioportfolio.com netdoctor.co.uk ukmi.nhs.uk urlm.co.uk btgplc.com dorsetformulary.nhs.uk formulary.cht.nhs.uk yelp.co.uk medicines.org.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/8.5 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

you are viewing content for the region united states certain btg products may not be available within the chosen location and indications may differ from your country's approved use. change to canada » remain viewing united states » digoxin toxicity symptoms diagnosing about digifab® production mechanism of action efficacy administering digifab® dosing and storage guidelines how to order resources faqs contact us this website is intended for us healthcare professionals only country: usa (change) canada usa important safety information full prescribing information digoxin toxicity symptoms diagnosing about digifab® production mechanism of action efficacy administering digifab® dosing and storage guidelines how to order resources faqs contact us digoxin toxicity can be difficult to recognize signs and symptoms of life-threatening or potentially life-threatening digoxin (also known as digitalis) toxicity include, but are not limited to, severe ventricular arrhythmias (including ventricular tachycardia or fibrillation), progressive bradycardia, second- or third-degree heart block not responsive to atropine, serum potassium levels exceeding 5.5 meq/l in adults or 6 meq/l in children with rapidly progressive signs and symptoms of digoxin toxicity, and neurologic symptoms (eg, visual disturbances, disorientation, and confusion). 1,2 digoxin is indicated to treat patients with mild to moderate heart failure an estimated 5.8 million individuals living in the united states have heart failure, with 670,000 new cases occurring each year. 3 -- who's at risk for digoxin toxicity? risk factors for digoxin toxicity include advanced age (>80 years); a decrease in renal clearance or loss of renal function due to chronic disease, hypokalemia, hypomagnesemia, and hypothyroidism; and use of multiple concomitant prescription drugs like macrolide antibiotics or drugs that impair renal function or cause hypokalemia. 2,4 life-threatening digoxin toxicity can be difficult to recognize digifab® digoxin immune fab (ovine) is a treatment for patients with life-threatening or potentially life-threatening digoxin toxicity or overdose and is clinically proven to effectively clear digoxin from the body. digoxin toxicity can be difficult to recognize in patients whose health may already be compromised. since the signs and symptoms are non-specific, knowing what to look for is important in order to effectively treat digoxin toxicity. read about digoxin toxicity » it is estimated that 5.8 million individuals in the us have chronic heart failure 3 references digifab ® [prescribing information]. btg international inc. january 2012. schreiber d. toxicity, digitalis. emedicine from webmd web site. http://emedicine.medscape.com/article/814404-print. updated january 4, 2017. accessed august 21, 2018. lloyd-jones d, adams rj, brown tm, et al. executive summary: heart disease and stroke statistics--2010 update: a report from the american heart association. wofford jl, ettinger wh. risk factors and manifestations of digoxin toxicity in the elderly. am j emerg med. 1991;9(suppl 1):11-15. to report an adverse event or for 24-hour medical information, call 1-877-377-3784 indications and usage digifab ® is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose, including: important safety information warnings and precautions known suicidal or accidental consumption of fatal doses of digoxin: 10 mg or more of digoxin in healthy adults, or 4 mg (or more than 0.1 mg/kg) in healthy children, or ingestion of an amount that can cause steady state serum concentrations of ≥10 ng/ml; chronic ingestions causing steady-state serum digoxin concentrations >6 ng/ml in adults or 4 ng/ml in children; manifestations of life-threatening toxicity of digoxin overdose such as severe ventricular arrhythmias, progressive bradycardia, and second or third degree heart block not responsive to atropine, serum potassium levels exceeding 5.5 meq/l in adults or 6 meq/l in children with rapidly progressive signs and symptoms of digoxin toxicity. general: suicidal ingestion may result from more than one drug. consider toxic effects of other drugs or poisons in cases where signs and symptoms of digitalis toxicity are not relieved by administration of digifab ® . rapid drop in serum potassium concentration may occur after treatment. monitor frequently. patients with poor cardiac function may deteriorate secondary to the withdrawal of the inotropic action of digoxin by digifab ® . monitor frequently and provide additional inotropic support if needed. postpone re-digitalization, if possible, until the fab fragments have been eliminated; this may require several days or a week or longer in patients with impaired renal function. hypersensitivity reactions: anaphylaxis and hypersensitivity reactions are possible. carefully monitor patients for signs and symptoms of an acute allergic reaction and if one occurs, stop the infusion and treat immediately with appropriate emergency medical care. patients with known allergies to sheep protein or those who have previously received intact ovine antibodies or fab are particularly at risk for an anaphylactic reaction. do not administer digifab ® to patients with a known history of hypersensitivity to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available. use of digifab ® in renal failure: the elimination half-life of digifab® in renal failure has not been clearly defined. monitor patients with severe renal failure who receive digfab ® for a prolonged period for possible recurrence of toxicity. monitoring of free (unbound) digoxin concentrations after the administration may be appropriate laboratory tests: digifab ® may interfere with digitalis immunoassay measurements. thus, standard serum digoxin concentration measurements may be clinically misleading until the fab fragments are eliminated from the body. this may take several days or a week or more in patients with markedly impaired renal function. if possible, obtain serum digoxin samples before digifab ® administration to establish the level of serum digoxin at the time of diagnosis. the total serum digoxin concentration may rise precipitously following administration of digifab®, but this will be almost entirely bound to the fab fragment and not able to react with receptors in the body. adverse reactions the most common adverse reactions (>7%) related to digifab ® administration are worsening congestive heart failure (13%), hypokalemia (13%) and worsening atrial fibrillation (7%). terms of use this website (the “website”) is owned by btg international inc. ("btg") and is operated by btg and its selected technology partners, which have agreed to comply with the btg privacy policy posted on the website (the “privacy policy”). please be sure to read this privacy policy before using or submitting information to this website. this site is governed solely by applicable federal and state laws and governmental regulations in the united states. use of this website constitutes your consent to application of such laws and regulations and to the terms of our privacy policy. whenever you submit information via this website, you consent to the collection, use, and disclosure of that information in accordance with this privacy policy. your use of this website is subject to our legal notice and terms of use. btg and the btg roundel logo are registered trademarks of btg international ltd. digifab ® is a registered trademark of btg international inc. btg specialty solutions center ™ is a trademark of btg international ltd. us-dgf-1800014 © 2018 btg international inc. all rights reserved. privacy policy site map

URL analysis for digifab.co.uk

https://digifab.health/en-US/en-us/resources
https://digifab.health/en-US/en-us/digoxin-toxicity/symptoms
https://digifab.health/en-US/#isi
https://digifab.health/en-US/digifab/media/digifabcontent/pdfs/digifab_package_insert.pdf
https://digifab.health/en-US/en-us/contact-us
https://digifab.health/en-US/en-us/digoxin-toxicity/diagnosing
https://digifab.health/en-US/en-us/about-digifab/efficacy
https://digifab.health/en-US/en-us/about-digifab/mechanism-of-action
https://digifab.health/en-US/privacy-policy
https://digifab.health/en-US/site-map
https://digifab.health/en-US/en-us/digoxin-toxicity
https://digifab.health/en-US/en-us/administering-digifab/guidelines
https://digifab.health/en-US/en-us/about-digifab
https://digifab.health/en-US/en-us
https://digifab.health/en-US/en-us/

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain name:
digifab.co.uk

Registrant:
Protherics Medicines Development Ltd

Registrant type:
Unknown

Registrant's address:
5 Fleet Place
London
London
EC4M 7RD
United Kingdom

Data validation:
Nominet was able to match the registrant's name and address against a 3rd party data source on 26-Jul-2016

Registrar:
Markmonitor Inc. t/a MarkMonitor Inc. [Tag = MARKMONITOR]
URL: http://www.markmonitor.com

Relevant dates:
Registered on: 01-Dec-2003
Expiry date: 01-Dec-2018
Last updated: 31-Oct-2016

Registration status:
Registered until expiry date.

Name servers:
ns1.markmonitor.com
ns2.markmonitor.com
ns3.markmonitor.com
ns4.markmonitor.com
ns5.markmonitor.com
ns6.markmonitor.com
ns7.markmonitor.com

WHOIS lookup made at 00:13:51 15-Dec-2017

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2017.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER co.uk.whois-servers.net

  ARGS digifab.co.uk

  PORT 43

  TYPE domain

OWNER

  ORGANIZATION Protherics Medicines Development Ltd

TYPE
Unknown

ADDRESS
5 Fleet Place
London
London
EC4M 7RD
United Kingdom
Data validation:
Nominet was able to match the registrant's name and address against a 3rd party data source on 26-Jul-2016

DOMAIN

  SPONSOR Markmonitor Inc. t/a MarkMonitor Inc. [Tag = MARKMONITOR]

  CREATED 2003-12-01

  CHANGED 2016-10-31

STATUS
Registered until expiry date.

NSERVER

  NS1.MARKMONITOR.COM 64.124.69.50

  NS2.MARKMONITOR.COM 162.88.60.13

  NS3.MARKMONITOR.COM 162.88.61.15

  NS4.MARKMONITOR.COM 162.88.60.15

  NS5.MARKMONITOR.COM 162.88.61.17

  NS6.MARKMONITOR.COM 162.88.60.17

  NS7.MARKMONITOR.COM 162.88.61.19

  NAME digifab.co.uk

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .